Activities and Presentations
Activities and Presentations
Select Year
- ●2024
- ●2023
- ●2022
- RemeGen 2025 Annual Results PDF
- Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: updated results PDF
- JP Morgan Healthcare Conference PDF
- A Phase 1/2 Study of RC148 (PD-1/VEGF bispecific antibody) monotherapy or in combination with docetaxel for the treatment of first- or second-line locally advanced or metastatic non-small-cell lung cancer (la/mNSCLC) without actionable genomic alterations (AGA) PDF
- NEJM：Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer PDF
- 2025 ESMO：Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression PDF
- RemeGen 2025 Q3 Report PDF
- RemeGen 2025 H1 Report PDF
- Remegen JPM 2025 PDF
- RemeGen 2025 Q1 Report PDF
No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
（+86）535-3573511
Official WeChat